Abstract
Objective: SARS-CoV-2 vaccinations have demonstrated vaccine-immunogenicity in healthy volunteers, however, efficacy in immunosuppressed patients is less well characterised. There is an urgent need to address the impact of immunosuppression on vaccine immunogenicity.
Methods: Serological, T-cell ELISpot, cytokines and immunophenotyping were used to assess vaccine responses (either BNT162b2 mRNA or ChAdOx1 nCoV-19) in double-vaccinated patients receiving immunosuppression for renal transplants or haematological malignancies (n = 13). Immunological responses in immunosuppressed patients (VACC-IS) were compared to immunocompetent vaccinated (VACC-IC, n = 12), unvaccinated (UNVACC, n = 11) and infection-naïve unvaccinated (HC, n = 3) cohorts.
Results: No significant different differences in T-cell responses were observed between VACC-IS and VACC-IC (92%) to spike-peptide (S) stimulation. UNVACC had the highest T-cell non-responders (n = 3), whereas VACC-IC and VACC-IS both had one T-cell non-responder. No significant differences in humoral responses were observed between VACC-IC and VACC-IS, with 92% (12/13) of VACC-IS patients demonstrating seropositivity. One VACC-IS failed to seroconvert, however had detectable T-cell responses. All VACC-IC participants were seropositive for anti-spike antibodies. VACC-IS and VACC-IC participants elicited strong Th1 cytokine response with immunodominance towards S-peptide. Differences in T-cell immunophenotyping were seen between VACC-IS and VACC-IC, with lower CD8 + activation and T-effector memory phenotype observed in VACC-IS.
Conclusion: SARS-CoV-2 vaccines are immunogenic in patients receiving immunosuppressive therapy, with responses comparable to vaccinated immunocompetent participants. Lower humoral responses were seen in patients treated with B-cell depleting therapeutics, but with preserved T-cell responses. We suggest further work to correlate both protective immunity and longevity of these responses in both healthy and immunosuppressed patients.
Keywords: COVID-19; Immunosuppressed; SARS-CoV-2; Vaccine immunogenicity.
【저자키워드】 COVID-19, SARS-CoV-2, vaccine immunogenicity., Immunosuppressed, 【초록키워드】 Efficacy, therapy, Cytokines, T-cell Response, Immunosuppression, haematological malignancies, SARS-CoV-2 vaccines, cytokine, CD8, SARS-CoV-2 vaccine, memory, BNT162b2, Immunophenotyping, Humoral response, Transplant, protective immunity, vaccine response, response, Patient, immunological responses, Seropositivity, phenotype, humoral responses, T-cell, Longevity, serological, ChAdOx1, seropositive, immunodominance, anti-spike antibodies, ChAdOx1 nCoV-19, T-cell responses, SARS-CoV-2 vaccination, immunosuppressed patients, BNT162b2 mRNA, immunosuppressive therapy, B-cell, Vaccinations, Immunosuppressed, immunosuppressive, vaccine immunogenicity, vaccine responses, Activation, Participants, significant difference, no significant differences, healthy volunteers, naïve, cohorts, participant, immunogenic, responders, renal, seroconvert, Lower, haematological malignancy, non-responder, difference, T-cell ELISpot, Th1 cytokine, highest, healthy, detectable, receiving, were used, less, demonstrated, comparable, elicited, depleting, immunosuppressed patient, patients treated, preserved, 【제목키워드】 Humoral response, SARS-CoV-2 vaccination, immunosuppressed patient,